Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DR-0201 in Healthy Volunteers
NCT06008652Phase 1Completed
- Sponsor
- Dren Bio
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in B-cell non-Hodgkin lymphoma and systemic lupus erythematosus (SLE) comparing DR-0201 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events up to 57 days. Started Nov 2023; status: completed.
02
Drugs
dr-0201
03
Conditions
B-cell non-Hodgkin lymphomasystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06008652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008652.